Hospital

Rajinder Shiwach, MD, MRCPsych, outlines how pharmacists can strengthen retention, patient education, and access to rapid induction strategies for opioid use disorder treatment.

Environmental factors significantly influence the rising rates of type 2 diabetes in children.

Richard Kovacs, MD, explains how switching from high-sodium to low-sodium oxybate led to meaningful blood pressure reductions and lower cardiovascular risk in patients with narcolepsy.

Rajinder Shiwach, MD, MRCPsych, discusses how rapid induction with extended-release buprenorphine improves patient retention and maintains comparable efficacy and tolerability to standard induction methods.

COVID-19 mRNA vaccines enhance immune checkpoint inhibitor effectiveness in cancer therapy, significantly improving survival rates for patients with advanced tumors.

The FDA approves a simplified single-injection treatment for ulcerative colitis, enhancing patient experience with monthly dosing convenience.

Oncologists increasingly embrace cell and gene therapies, yet barriers like cost and perceptions of risk hinder broader adoption.

Expert shares notable findings presented at the 2025 IMS Annual Meeting.

The FDA updates sotatercept's label, enhancing treatment options for pulmonary arterial hypertension and reducing severe clinical events.

FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma, enhancing treatment options and survival rates for patients with limited therapies.

Personalized cancer vaccines target tumor heterogeneity, enhancing immune responses and improving treatment outcomes in diverse cancer types.

Experts at ESMO 2025 highlight antibody-drug conjugates in HER2-positive metastatic breast cancer treatment.

Emerging biomarkers and targeted therapies are reshaping the landscape of lung cancer treatment and drug development.

Advances in targeted therapies, combination approaches, and novel treatment strategies are shaping the management of drug-resistant lung cancer.

Insights from ESMO 2025 highlight advancements in non-small cell lung cancer treatment, focusing on novel therapies and molecular diagnostics.

New data from the NATALEE trial reveals ribociclib significantly improves invasive disease-free survival in HR+/HER2– early breast cancer.

Adjuvant abemaciclib plus endocrine therapy significantly enhances overall survival in high-risk HR-positive HER2-negative breast cancer.

Durvalumab combined with FLOT shows significant survival benefits for patients with resectable gastroesophageal junction cancer, regardless of PD-L1 status.

Nivolumab plus chemotherapy and ipilimumab show significant long-term survival benefits for advanced esophageal squamous cell carcinoma.

Whether they are collaborating with other health care professionals, helping with medication adherence, or educating patients, pharmacists have a crucial role in every setting.

Ron Lanton outlines enforcement uncertainty and downstream effects on biosimilars, specialty drugs, and pharmacy supply chains under most favored nation pricing proposals.

Research reveals that statins and metformin enhance survival rates in early-stage triple-negative breast cancer, offering hope for affordable treatment options.

GLP-1 receptor agonists show potential as innovative treatments for alcohol and substance use disorders, addressing critical public health needs.

Primary care clinics enhance diabetes management by implementing continuous glucose monitors, improving access to essential care for patients nationwide.

The move emphasizes the need for vigilant monitoring.

Inhaled insulin Afrezza offers a rapid-acting alternative for children with type 1 diabetes, enhancing blood glucose control and patient satisfaction.

Invasive lobular carcinoma poses unique challenges in detection and treatment, highlighting the urgent need for targeted research and improved survival strategies.

The pharmaceutical giant will reportedly lower its drug prices to align with most-favored-nation status.